Publications 2022

Cyll K, Löffeler S, Carlsen B, Skogstad K, Plathan ML, Landquist M, Haug ES (2022)
No significant difference in intermediate key outcomes in men with low- and intermediate-risk prostate cancer managed by active surveillance
Sci Rep, 12 (1), 6743
DOI 10.1038/s41598-022-10741-8, PubMed 35468921

Publications 2021

Cyll K, Kleppe A, Kalsnes J, Vlatkovic L, Pradhan M, Kildal W, Tobin KAR, Reine TM, Wæhre H, Brennhovd B, Askautrud HA, Skaaheim Haug E, Hveem TS, Danielsen HE (2021)
PTEN and DNA Ploidy Status by Machine Learning in Prostate Cancer
Cancers (Basel), 13 (17)
DOI 10.3390/cancers13174291, PubMed 34503100

Publications 2020

Ersvaer E, Hveem TS, Vlatkovic L, Brennhovd B, Kleppe A, Tobin KAR, Pradhan M, Cyll K, Waehre H, Kerr DJ, Danielsen HE (2020)
Prognostic value of DNA ploidy and automated assessment of stroma fraction in prostate cancer
Int J Cancer, 147 (4), 1228-1234
DOI 10.1002/ijc.32832, PubMed 31846064

Publications 2019

Ersvær E, Kildal W, Vlatkovic L, Cyll K, Pradhan M, Kleppe A, Hveem TS, Askautrud HA, Novelli M, Wæhre H, Liestøl K, Danielsen HE (2019)
Prognostic value of mitotic checkpoint protein BUB3, cyclin B1, and pituitary tumor-transforming 1 expression in prostate cancer
Mod Pathol, 33 (5), 905-915
DOI 10.1038/s41379-019-0418-2, PubMed 31801961

Publications 2017

Cyll K, Ersvær E, Vlatkovic L, Pradhan M, Kildal W, Avranden Kjær M, Kleppe A, Hveem TS, Carlsen B, Gill S, Löffeler S, Haug ES, Wæhre H, Sooriakumaran P, Danielsen HE (2017)
Tumour heterogeneity poses a significant challenge to cancer biomarker research
Br J Cancer, 117 (3), 367-375
DOI 10.1038/bjc.2017.171, PubMed 28618431

Kildal W, Pradhan M, Cyll K, Jacobsen JE, Kristensen GB, Danielsen HE (2017)
[Properties of cancer cell DNA affects the prognosis]
Tidsskr Nor Laegeforen, 137 (19)
DOI 10.4045/tidsskr.16.0966, PubMed 29043733

Kildal W, Pradhan M, Cyll K, Jacobsen JE, Kristensen GB, Danielsen HE (2017)
Characteristics of tumor cell DNA affect prognosis
Tidsskr. Nor. Laegeforen., 137 (19), 1519-1523